Furthermore, when the obesogenic status was reduced, the expression of amylin and GLP-1 receptors in the DVC remained stable, suggesting that even in a weight-reduced state form obesity, the DVC GLP-1R and amylin receptors theoretically remain as viable drug targets for sustaining weight loss with continued pharmacotherapy. Here, IAPP is linked to obesity due to melanocortin 4 receptor deficiency.